Organogenesis Holdings (ORGO) Cash from Financing Activities (2016 - 2026)

Organogenesis Holdings' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 883.12% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$35.5 million (down 226.0% YoY), while the FY2025 annual figure was -$17.4 million, down 162.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$20.2 million, down from -$4.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $33.6 million in Q4 2024, with the low at -$20.2 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$1.7 million (2024), against an average of -$1.0 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 5630.77% in 2023, then soared 1993.58% in 2024.
• Organogenesis Holdings' Cash from Financing Activities stood at -$1.9 million in 2022, then rose by 5.23% to -$1.8 million in 2023, then jumped by 1993.58% to $33.6 million in 2024, then plunged by 114.29% to -$4.8 million in 2025, then tumbled by 320.32% to -$20.2 million in 2026.
• Business Quant data shows ORGO's Cash from Financing Activities at -$20.2 million in Q1 2026, -$4.8 million in Q4 2025, and -$10.2 million in Q3 2025.